Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 10:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–29 of 5 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Stage IIIB Cutaneous Melanoma AJCC v7 Clear all

Active, not recruiting Phase 2 Interventional Results available

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT01134614

View directory record Official record

Conditions: Advanced Melanoma, Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Interventions: Ipilimumab, Sargramostim; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 258
States / cities: Birmingham, Alabama • Palo Alto, California • Rancho Mirage, California + 197 more

Source: ClinicalTrials.gov public record

Updated Apr 27, 2026 · Synced May 21, 2026, 10:15 PM EDT

Completed Phase 2 Interventional Results available

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

NCT01807182

View directory record Official record

Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Metastatic Melanoma
Interventions: Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Therapeutic Tumor Infiltrating Lymphocytes; Biological · Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Source: ClinicalTrials.gov public record

Updated Nov 9, 2022 · Synced May 21, 2026, 10:15 PM EDT

Completed Phase 2 Interventional Results available

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

NCT01835145

View directory record Official record

Conditions: Recurrent Uveal Melanoma, Stage III Uveal Melanoma AJCC v7, Stage IIIA Uveal Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Uveal Melanoma AJCC v7
Interventions: Cabozantinib S-malate, Dacarbazine, Laboratory Biomarker Analysis, Temozolomide; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 224
States / cities: Birmingham, Alabama • Anchorage, Alaska • Burbank, California + 141 more

Source: ClinicalTrials.gov public record

Updated Aug 3, 2022 · Synced May 21, 2026, 10:15 PM EDT

Active, not recruiting Phase 2 Interventional Results available

Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

NCT01708941

View directory record Official record

Conditions: Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Ipilimumab, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 277
States / cities: Birmingham, Alabama • Aurora, Colorado • Boulder, Colorado + 184 more

Source: ClinicalTrials.gov public record

Updated Apr 29, 2026 · Synced May 21, 2026, 10:15 PM EDT

Completed Phase 2 Interventional Results available

Neoadjuvant and Adjuvant Checkpoint Blockade

NCT02519322

View directory record Official record

Conditions: Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage III Acral Lentiginous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Acral Lentiginous Melanoma AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
Interventions: Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Relatlimab, Therapeutic Conventional Surgery; Biological · Other · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Source: ClinicalTrials.gov public record

Updated Apr 4, 2024 · Synced May 21, 2026, 10:15 PM EDT